The hydrochloride salt of 2-Isopropyl-4-(Methylaminomethyl)Thiazole, CAS 154212-60-9, functions primarily as a heterocyclic building block. Its secondary amine terminus and thiazole ring enable selective N-alkylation and subsequent cyclocondensation. Industrial procurement specifications typically demand purity exceeding 99.0% (HPLC, UV detection at 254 nm), with single impurity limits set at ≤ 0.3% and residual solvents controlled per USP <467>. Storage under inert gas at 2–8 °C is mandatory to prevent oxidative discoloration of the aminomethyl group.
Does the Freebase Form Enable a Non-Hygroscopic Intermediate for Azole Antifungals?
The freebase liberated from the hydrochloride salt participates in amide coupling reactions with 2,4-difluorophenylacetic acid derivatives, a step central to constructing triazole antifungal candidates. In a documented scaled-up campaign executed in a 2000 L glass-lined reactor, the freebase was generated in situ by treatment with 1.05 eq. of aqueous sodium hydroxide in a toluene-water biphase at 20–25 °C. After phase separation and azeotropic drying to a Karl Fischer endpoint of < 100 ppm H₂O, the toluene solution was added dropwise to a pre-formed mixed anhydride prepared from the acid fragment and pivaloyl chloride. The addition rate was constrained to maintain an internal temperature below −5 °C, preventing racemization of an adjacent chiral center in the advanced intermediate. Amide bond formation proceeds with in-process control (IPC) by TLC (ethyl acetate/hexane 1:1). Upon completion, the organic layer is washed sequentially with 5% w/w citric acid and saturated brine. Crystallization from isopropanol/water (3:1 v/v) isolates the penultimate intermediate in 85–92% yield. The thiazole moiety remains intact through subsequent deprotection and sulfonation steps that yield the final triazole API. Residual thiazole-derived impurities are controlled below 0.10% by achiral reversed-phase HPLC (C18, acetonitrile/phosphate buffer pH 3.0). ICH Q3A guidelines govern the qualification threshold for this late-stage intermediate, with the specification for the methylaminomethyl analog set at ≤ 0.15% relative to the azole core.Process deviation investigation from a pilot-plant batch (Lot F-0224-117)
A failed amide coupling batch traced to incomplete freebase liberation was investigated. Residual hydrochloride salt in the organic phase, invisible to standard IPC, was quantified by chloride ion chromatography with a detection limit of 5 ppm. Values exceeding 50 ppm Cl⁻ in the dried toluene stream correlated with a yield drop of 15–20% relative to validated ranges. The corrective action involved installing an in-line conductivity probe on the phase-separation decanter, with a defined reject parameter of >10 µS/cm in the organic outlet stream, forcing automatic recycle until complete phase break.
Ritonavir Structural Analog Intermediates Fabricated via N-Alkylation
The secondary amine of 2-Isopropyl-4-(Methylaminomethyl)Thiazole undergoes N-alkylation with chloromethylthiazole electrophiles in the manufacture of HIV protease inhibitor scaffolds structurally related to ritonavir. The reaction is typically conducted in anhydrous acetonitrile with 1.3–1.5 eq. of powdered potassium carbonate as the acid scavenger. Granulometry of the potassium carbonate base is critical: sieved fractions below 75 µm (200 mesh) provide adequate surface area, whereas coarse granular grades (>250 µm) slow the heterogeneous reaction rate and increase the risk of stalled conversion, leaving residual starting material that co-elutes with the product during silica gel chromatography. Reaction monitoring by GC-FID tracks the disappearance of the alkyl chloride electrophile. The dialkylated product is isolated by extraction into methyl tert-butyl ether (MTBE) and concentrated under vacuum at < 45 °C. Elevated distillation temperatures (> 55 °C) have been associated with the formation of a dimeric impurity via intermolecular transamination; this impurity, once exceeding 0.5 area%, is not reliably purged by recrystallization. The final intermediate specification mandates a heavy metals content below 10 ppm (USP <231>) and a residual palladium limit of < 1 ppm if a prior Sonogashira or Suzuki coupling was employed upstream. The N-alkylated scaffold is subsequently elaborated through carbamate formation and sulfonamide coupling to yield the peptidomimetic backbone characteristic of this therapeutic class.When a Methylaminomethyl Substituent Becomes the Anchor Point for Bcr-Abl Kinase Inhibitor Cores
In the synthesis pathway for certain Bcr-Abl tyrosine kinase inhibitor analogs, the aminomethyl arm of 2-Isopropyl-4-(Methylaminomethyl)Thiazole serves as a pre-installed amine handle for constructing the benzamide pharmacophore. The hydrochloride salt is first neutralized with aqueous sodium bicarbonate and extracted into dichloromethane. The dried organic layer is added to a solution of 4-chloromethyl-N-(4-pyridinyl)benzamide in N,N-dimethylformamide (DMF) at 0–5 °C. The addition is performed under a nitrogen counterflow to exclude atmospheric moisture, which can hydrolyze the benzyl chloride moiety to the corresponding benzyl alcohol, a dead-end impurity that must be maintained below 0.2% by HPLC (gradient, 10 mM ammonium acetate pH 6.8 / acetonitrile). The stoichiometric ratio of the thiazole amine to the benzyl chloride is held at 1.02:1.00; excess amine is removed post-reaction by an acetic acid wash (0.5 M, 3 × reactor volume). The resulting tertiary amine intermediate is then subjected to a reductive amination with N-Boc-piperidine-4-carboxaldehyde using sodium triacetoxyborohydride (1.4 eq.) in 1,2-dichloroethane. The Boc group is cleaved with HCl in dioxane (4 M), and the final API candidate is crystallized as the dihydrochloride salt from ethanol/water. Ion chromatography confirms the chloride counterion stoichiometry deviates by no more than ± 5% from the theoretical dihydrochloride value, a critical attribute for both dissolution rate and hygroscopicity in solid oral dosage forms.Thermal stability screening of the N-benzylated intermediate
Differential scanning calorimetry (DSC) at a ramp rate of 10 °C/min under nitrogen reveals an exothermic decomposition onset at 187.3 °C with an energy release of 890 J/g. Accelerating rate calorimetry (ARC) data indicate the self-accelerating decomposition temperature (SADT) is 112 °C. This necessitates jacketed reactor temperature limits not exceeding 80 °C during any post-reaction distillation or solvent swap operations involving this specific penultimate compound. Process safety relief system sizing was based on a phi-factor of 1.05 in the ARC test, and the vent area was calculated per DIERS methodology for a tempered hybrid system.
Veterinary coccidiostats represent a well-characterized application vector for the methylaminomethyl thiazole core. 2-Isopropyl-4-(Methylaminomethyl)Thiazole is converted into the corresponding guanidine derivative via treatment with cyanamide (1.2 eq.) in ethanol at reflux (78 °C). The reaction is catalyzed by 0.05 eq. of concentrated hydrochloric acid and proceeds to completion in 6–8 hours. The ethanol is distilled under vacuum, and the residue is triturated with acetone to crystallize the guanidine intermediate. This intermediate is then condensed with diethyl ethoxymethylenemalonate (EMME) in a Gould-Jacobs cyclization protocol. The cyclization is carried out in Dowtherm A at 250 °C over 45 minutes under a nitrogen sweep to remove the ethanol byproduct. The resulting pyrido[2,3-d]pyrimidine heterocycle is further functionalized to the 4-hydroxyquinoline-3-carboxylate scaffold that defines the coccidiostat pharmacophore. The targeted species are Eimeria tenella and Eimeria maxima, with the final premix formulation blended onto corn cob grits at an inclusion rate calculated to deliver 60–125 ppm of active in finished broiler feed. Regulatory compliance for the veterinary premix manufacturing process is benchmarked against VICH GL18 residual solvent guidelines. Gas chromatographic headspace analysis of the final premix must confirm methanol ≤ 3,000 ppm, dichloromethane ≤ 600 ppm, and N,N-dimethylformamide ≤ 880 ppm, per VICH Class 2 and Class 3 residual solvent limits extrapolated from human pharmaceutical threshold toxicological concerns.
